|
Oct 3
|
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
|
|
Sep 12
|
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
|
|
Sep 9
|
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
|
|
Aug 29
|
TC BioPharm secures European patent for cancer treatment
|
|
Aug 28
|
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
|
|
Aug 28
|
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
|
|
Jul 31
|
TCBP Announces Plan to Implement ADS Ratio Change
|
|
Jul 22
|
TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia
|
|
Feb 15
|
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
|
|
Feb 14
|
TCBP Provides Shareholder Update and Highlights Upcoming Milestones
|
|
Dec 22
|
TC BioPharm Announces Closing of $3.5 Million Public Offering
|
|
Dec 19
|
TC BioPharm Announces Pricing of $3.5 Million Public Offering
|
|
Dec 18
|
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D
|
|
Nov 28
|
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
|
|
Nov 27
|
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
|
|
Apr 26
|
TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008
|
|
Feb 23
|
TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer
|
|
Feb 21
|
TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies
|